PDCD1 and non-small cell lung carcinoma: However, the majority of patients did not respond to single-agent PD-1/PD-L1 blockade therapy, and the objective response rate (ORR) was only about 15–25% in most solid tumors such as non-small cell lung cancer (NSCLC), head and neck, gastroesophageal, bladder, and urothelial cancers (1).